Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Trial of Neoadjuvant, Hypofractionated Radiation, With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy, in Stage 3 or High-risk Stage 2 Breast Cancer

NCT07188246 is registered in ClinicalTrials.gov with London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's as lead sponsor.

NCT NCT07188246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07188246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Trial of Neoadjuvant, Hypofractionated Radiation, With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy, in Stage 3 or High-risk Stage 2 Breast Cancer
Lead sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase
Phase 2
Overall status
Recruiting
Start date
January 19, 2026
Completion date
February 28, 2029
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer invasive, breast cancer stage ii, breast cancer stage iii, breast cancer triple negative